PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
March 13, 2026Frontiers in Oncology0 citationsOpen Access

Prognostic value of the pretreatment pan-immune-inflammation value in patients with head and neck squamous cell carcinoma: a systematic review and meta-analysis

View Full Paper
TLTe LiGLGenping Li

Key Points

  • To investigate the relationship between pretreatment pan-immune-inflammation value (PIV) and survival outcomes in patients with head and neck squamous cell carcinoma.
  • Conducted a systematic search of the literature across multiple electronic databases.
  • Focused on survival outcomes as the primary endpoint.
  • Utilized a random-effects model for data integration from 12 studies.
  • High PIV was associated with significantly poorer overall survival (HR = 2.62).
  • Patients in the high PIV group experienced worse disease-free survival (HR = 2.34).
  • Higher PIV correlated with a worse distal metastasis-free survival (HR = 2.04) and marginally poorer local recurrence-free survival (HR = 1.20).

Abstract

Background The prognostic significance of the pan-immune-inflammation value (PIV) in head and neck squamous cell carcinoma has been comprehensively documented. Nevertheless, its exact role remains ambiguous. The objective of this study is to perform a systematic exploration of the correlation between the pretreatment PIV and survival outcomes in this population. Methods An extensive and systematic search of the literature was conducted through electronic databases, including Web of Science, PubMed, and Embase. The search period covered from inception to October 1, 2025. The primary endpoint was survival outcomes. Hazard ratios (HRs) and their 95% confidence intervals (CIs) for survival outcomes were retrieved. A random-effects model was employed to integrate the pooled findings. This meta-analysis was prospectively registered with PROSPERO (CRD420251170558). Results A total of twelve studies, encompassing 5,056 patients, were included. The pooled results revealed that patients in the high PIV group exhibited significantly inferior overall survival (12 studies; HR = 2.62; 95% CI: 2.00 – 3.44; I² = 74%) and disease-free survival (9 studies; HR = 2.34; 95% CI: 1.69 - 3.26; I² = 79%) when compared to those in the low PIV group. Subgroup analyses buttressed the prognostic significance of PIV for overall survival and disease-free survival across diverse geographical regions, tumor stages, and treatment strategies. Moreover, evidence aggregated from limited studies indicated that a higher PIV was associated with a worse distal metastasis-free survival (3 studies; HR = 2.04; 95% CI: 1.13 - 3.67; P = 0.02; I² = 94%) and a marginally poorer local recurrence-free survival (3 studies; HR = 1.20; 95% CI: 1.00 - 1.44; P = 0.05; I² = 0%). Conclusions Our findings indicate that the pretreatment PIV has the potential to serve as a valuable biomarker for predicting the survival outcomes of patients with head and neck squamous cell carcinoma. Systematic review registration https://www.crd.york.ac.uk/prospero/ , identifier CRD420251170558.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Li et al. (2026) studied this question.

synapsesocial.com/papers/69b3aad702a1e69014ccb859https://doi.org/10.3389/fonc.2026.1743144
Ask AI
Helpful
Bookmark
Share
View Full Paper